AZACS


Also found in: Acronyms.

AZACS

Azithromycin in Acute Coronary Syndrome. A trial which asked whether the evidence suggesting an association between Chlamydia pneumoniae infection and coronary artery disease was real, and, if so, would short-term treatment with the macrolide antibiotic azithromycin reduce recurrent ischaemic events in patients admitted for unstable angina or acute myocardial infarction.
 
Endpoint
Death, recurrent MI, recurrent ischaemia necessitating revascularisation.

Logistics
Randomised, double-blind, placebo-controlled, multicentre; 1439 patients to receive azthromycin or placebo.
 
Conclusion
No association between Chlamydia pneumoniae infection and coronary artery disease (and thus, no benefit of azithromycin treatment).
References in periodicals archive ?
Confounding is another possibility, since 70% of the patients in AZACS and two-thirds in WIZARD were taking statins, which have anti-inflammatory effects that may have obscured the antibiotic benefit.
The incidence of clinical events in the 80% of AZACS participants who had positive titers for C.
Anderson said that while AZACS and WIZARD certainly don't provide any basis for routinely prescribing antibiotic therapy to prevent coronary events, they don't bury the underlying hypothesis, either.